

## TABLE OF CONTENTS

### OPENING REMARKS

Prof. H.G. Kristensen, Chair of the European Pharmacopoeia Commission .....	3
---	---

### OBJECTIVES, SCOPE AND BACKGROUND OF THE PROCEDURE

#### Scope of the procedure and links with the licensing authorities and inspection

Dr A. Artiges, Director of the European Directorate for the Quality of Medicines (EDQM) .....	7
--	---

#### Viewpoints of the parties concerned:

##### *Rapporteurs:*

Dr D. De Kaste, Chair of the Chemical Technical Advisory Board (TAB) for the Certification Procedure .....	11
Dr M. S. Ruiz, Chair of the TSE Technical Advisory Board (TAB) for the Certification Procedure .....	15

##### *Licensing authorities:*

Dr J.L. Robert, Chair of the Joint CPMP/CVMP Quality Working Party (EMEA) .....	17
Prof. J.H. Trouvin, Chair of the CPMP Biotechnology Working Party (EMEA) .....	19

##### *Industries*

Dr B. Poncioni, European Federation of Pharmaceutical Industries Association (EFPIA)....	23
Dr H. Leblanc, APIC Chairman, European Chemical Industry Council (CEFIC) .....	25
Prof. H.J. De Jong, Chair of the International Pharmaceutical Excipients Council – Europe (IPEC -Europe) .....	29

##### *EDQM*

Dr C. Pouget, Principal Scientific Officer Responsible for the Certification Unit (EDQM) .	31
--	----

Round Table Discussion .....	35
------------------------------	----

### HOW TO APPLY FOR A CEP

#### Constitution of a dossier: the administrative viewpoint

Dr A. McMath, Scientific Officer of the Certification Unit (EDQM) .....	43
---	----

#### Constitution of a dossier: critical points and recapitulation of the most common deficiencies

##### *For chemical quality evaluation*

Manufacturing method and quality control during manufacture including specific cases (several manufacturing methods, and / or sites, and/or several grades)

Dr W. Schlumbohm, BgVV (Germany), Rapporteur for the Certification Procedure and Member of the Chemical TAB .....	49
and Dr S. Steiner, Kt BE (Switzerland), Rapporteur for the Certification Procedure .....	53

Impurities originating from the route of synthesis including catalysts and residual solvents	
<b>Dr E. Souli</b> , National Organization for Medicines (EOF) (Greece), .....	57
and <b>Prof. J. P. Fournier</b> , Paris V University, Faculty of Pharmacy (France), .....	61
Rapporteurs for the Certification Procedure and Members of the Chemical TAB for the Certification Procedure	
Special case: fermentation products	
<b>Dr A. Ambrose</b> , MCA (United-Kingdom) .....	65
and <b>Prof. M. Terreni</b> , University of Pavia (Italy) .....	67
Rapporteurs for the Certification Procedure and Members of the Chemical TAB for the Certification Procedure	
<i>Follow-up to certification</i>	
Variations and Quinquennial Renewal: Revision of Monographs	
<b>Ms K. Brønnum-Hansen</b> , DKMA (Denmark), Rapporteur for the Certification Procedure and Member of the Chemical TAB for the Certification Procedure .....	71
Discussion .....	73
<i>For TSE risk products evaluation</i>	
General considerations	
<b>Mr F. Moutou</b> , AFFSA (France), Rapporteur for the TSE Certification Procedure .....	79
Specific cases: gelatin, tallow derivatives, foetal serum and media components	
<b>Dr H. Willkommen</b> , Paul-Ehrlich-Institut (Germany), Rapporteur for the TSE Certification Procedure and Member of the TSE TAB for the Certification Procedure .....	83
Discussion .....	87
FINAL CONCLUSIONS AND ROUND-TABLE DISCUSSION .....	91
BIOGRAPHICAL NOTES .....	99
FINAL LIST OF PARTICIPANTS .....	107